A MEDICAL technology company spun-out of the University of St Andrews has received £300,000 in funding from Mercia Fund Management and the Scottish Investment Bank.

MOFgen will use the seed investment to further the commercialisation of products aimed at reducing Healthcare Acquired Infections (HAIs), prevent procedural complications and improve healing rates.

The company was formed in 2013 to commercialise research into the development of metal-organic frameworks (MOFs) for biomedical applications. MOFs are powdery solids with microscopic pores that can be loaded with antibacterial, wound healing and anti-thrombotic agents such as antibiotics, bioactive gases and metal ions.

Professor Russell Morris, chief scientific officer at MOFgen Ltd, said: “We are delighted to secure this investment as we really believe that our technology will make a significant and positive difference for those people who suffer from chronic wounds and secondary infections.”